FY2017 EPS Estimates for Spark Therapeutics, Inc. (ONCE) Increased by Analyst
Spark Therapeutics, Inc. (NASDAQ:ONCE) – Analysts at Jefferies Group increased their FY2017 earnings estimates for Spark Therapeutics in a research note issued on Monday. Jefferies Group analyst G. Wang now anticipates that the brokerage will post earnings per share of ($3.57) for the year, up from their prior forecast of ($4.23). Jefferies Group has a “Hold” rating and a $57.00 price objective on the stock. Jefferies Group also issued estimates for Spark Therapeutics’ FY2018 earnings at ($2.41) EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $5.18 EPS.
A number of other equities analysts also recently issued reports on the company. Wedbush reiterated an “underperform” rating and set a $28.00 price target on shares of Spark Therapeutics in a research report on Monday, December 5th. Zacks Investment Research downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. Vetr downgraded Spark Therapeutics from a “buy” rating to a “hold” rating and set a $62.50 price target on the stock. in a research report on Tuesday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Spark Therapeutics in a research report on Monday, November 7th. Finally, Chardan Capital reiterated a “neutral” rating and set a $47.50 price target (down previously from $55.00) on shares of Spark Therapeutics in a research report on Monday, November 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. Spark Therapeutics currently has an average rating of “Hold” and an average target price of $60.69.
Spark Therapeutics (NASDAQ:ONCE) traded down 0.24% during trading on Wednesday, hitting $57.15. The stock had a trading volume of 49,145 shares. The company’s 50 day moving average is $53.39 and its 200-day moving average is $55.20. Spark Therapeutics has a 12 month low of $21.20 and a 12 month high of $65.99. The company’s market cap is $1.76 billion.
Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by $0.06. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.26 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.70) EPS.
In related news, insider Katherine A. High sold 10,000 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $60.30, for a total value of $603,000.00. Following the completion of the sale, the insider now owns 210,000 shares of the company’s stock, valued at $12,663,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 5,000 shares of the stock in a transaction that occurred on Monday, October 17th. The shares were sold at an average price of $54.66, for a total value of $273,300.00. Following the completion of the sale, the chief executive officer now directly owns 235,000 shares of the company’s stock, valued at approximately $12,845,100. The disclosure for this sale can be found here. 9.60% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of the stock. FMR LLC boosted its stake in Spark Therapeutics by 10.6% in the second quarter. FMR LLC now owns 4,499,326 shares of the company’s stock valued at $230,051,000 after buying an additional 432,868 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Spark Therapeutics by 9.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,906,496 shares of the company’s stock valued at $174,564,000 after buying an additional 248,309 shares in the last quarter. Vanguard Group Inc. boosted its stake in Spark Therapeutics by 28.9% in the second quarter. Vanguard Group Inc. now owns 1,512,600 shares of the company’s stock valued at $77,340,000 after buying an additional 338,720 shares in the last quarter. Baker BROS. Advisors LP bought a new stake in Spark Therapeutics during the third quarter valued at approximately $79,180,000. Finally, Lord Abbett & CO. LLC boosted its stake in Spark Therapeutics by 182.9% in the second quarter. Lord Abbett & CO. LLC now owns 1,165,207 shares of the company’s stock valued at $59,577,000 after buying an additional 753,377 shares in the last quarter. 82.98% of the stock is owned by hedge funds and other institutional investors.
About Spark Therapeutics
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.